|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.50 CHF | -0.79% |
|
-14.97% | -0.79% |
| Capitalization | 174M 217M 187M 162M 302M 19.68B 325M 2B 789M 9.39B 813M 796M 34.27B | P/E ratio 2025 * |
-
| P/E ratio 2026 * | - |
|---|---|---|---|---|---|
| Enterprise value | 174M 217M 187M 162M 302M 19.68B 325M 2B 789M 9.39B 813M 796M 34.27B | EV / Sales 2025 * |
2.46x | EV / Sales 2026 * | 1.67x |
| Free-Float |
69.07% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Santhera Pharmaceuticals Holding AG
More press releases
More news
| 1 day | -0.79% | ||
| 1 week | -14.97% | ||
| Current month | -0.79% | ||
| 1 month | +3.14% | ||
| 3 months | +20.19% | ||
| 6 months | -10.71% | ||
| Current year | -0.79% |
| 1 week | 12.4 |  | 14.66 |
| 1 month | 11.7 | | 15 |
| Current year | 11.7 | | 15 |
| 1 year | 9.38 | | 17.76 |
| 3 years | 5.9 | | 17.76 |
| 5 years | 5 | | 53.3 |
| 10 years | 5 | | 863.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Dario Eklund
CEO | Chief Executive Officer | 58 | 30/11/2019 |
Catherine Isted
DFI | Director of Finance/CFO | - | 23/02/2025 |
Marc Schrader
COO | Chief Operating Officer | - | 31/08/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Meier
CHM | Chairman | 63 | 29/06/2022 |
| Director/Board Member | 58 | 03/04/2017 | |
Shabir Hasham
BRD | Director/Board Member | - | 09/04/2024 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.79% | -14.97% | -10.71% | +38.73% | 217M | |
| +0.85% | +1.33% | -8.03% | -32.50% | 65.56B | |
| +0.29% | +0.64% | +12.25% | -9.87% | 8.5B | |
| -0.85% | -1.74% | +29.95% | +35.20% | 8.37B | |
| +0.67% | -3.76% | +9.75% | +66.30% | 6.4B | |
| -0.28% | -4.77% | -19.48% | +113.76% | 5.47B | |
| -1.05% | -8.18% | +179.31% | +32.82% | 4.06B | |
| -0.70% | -2.10% | -10.96% | -17.61% | 3.01B | |
| -0.52% | -2.17% | +32.49% | +24.25% | 2.87B | |
| +1.89% | +3.79% | +56.78% | +44.94% | 2.77B | |
| Average | -0.05% | -2.75% | +27.13% | +29.60% | 10.72B | |
| Weighted average by Cap. | +0.48% | +0.05% | +6.79% | -5.52% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 70.61M 87.99M 75.85M 65.74M 122M 7.98B 132M 812M 320M 3.81B 330M 323M 13.9B | 104M 130M 112M 97.1M 181M 11.79B 195M 1.2B 473M 5.62B 487M 477M 20.54B |
| Net income | - | - |
| Net Debt | - | - |
More financial data
* Estimated data
Employees
79
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/01/26 | 12.50 CHF | -0.79% | 174,460 |
| 15/01/26 | 12.60 CHF | -4.98% | 137,388 |
| 14/01/26 | 13.26 CHF | -4.47% | 72,793 |
| 13/01/26 | 13.88 CHF | -4.67% | 92,385 |
| 12/01/26 | 14.56 CHF | -0.95% | 148,338 |
Delayed Quote Swiss Exchange, January 16, 2026 at 04:31 pm
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
12.50CHF
Average target price
30.00CHF
Spread / Average Target
+140.00%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SANN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition